Cross-neutralization Capacity of Immune Serum from Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization against Multiple Individual Polioviruses

ABSTRACT

Introduction: Sabin strain inactivated poliovirus vaccine (sIPV) developed by Sinovac Biotech Co., Ltd., has shown good safety and immunogenicity against parental strains among infants in several finished pre-licensure clinical trials.

Areas covered: To further study the neutralizing capacity of investigational sIPV immune serum against Sabin, Salk and recently circulating poliovirus strains, neutralization assay against ten individual strains was performed on backup serum collected from 250 infant participants of the finished phase II clinical trial.

Expert commentary:: The sIPV can generate good immunogenicity against Sabin, Salk and recently circulating poliovirus strains. Taking into account its lower containment requirements and financial costs compared with the conventional Salk strain inactivated poliovirus vaccine, sIPV is an affordable and practical option for polio eradication.

KEYWORDS:

• Cross-neutralization
• immune serum
• inactivated poliovirus vaccine
• Sabin strain

Declaration of interest

G. Zeng, W. Han, D. Jiang, and T. Zhu are currently employed at Sinovac Biotech Co., Ltd. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Author contributions

YH and GZ were responsible for the trial design and participated in the literature review. KC was responsible for study coordination and participated in data interpretation. WH participated in data interpretation and drafted the manuscript. WX and DJ were responsible for the neutralization testing. TZ participated in the data collection and literature review. ZJ was responsible for data analysis. All authors approved the final version of the manuscript and agree to be accountable for all aspects of the work.

Additional information

Funding

This paper was not funded.